Avodart (dutasteride), a new drug for benign prostatic hyperplasia (BPH)

GlaxoSmithKline is now marketing Avodart (dutasteride), a new drug for benign prostatic hyperplasia (BPH).

It's a 5-alpha reductase inhibitor...similar to Proscar.

Blocking this enzyme reduces the production of dihydrotestosterone which stimulates the growth of prostate cells.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote